[Federal Register Volume 64, Number 76 (Wednesday, April 21, 1999)]
[Notices]
[Page 19572]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-9907]
-----------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Issuer Delisting; Notice of Application to Withdraw from Listing
and Registration; (K-V Pharmaceutical Company, Class A Common Stock,
Par Value $.01 Per Share, and Class B Common Stock, Par Value $0.1 Per
Share) File No. 1-9601
April 14, 1999.
K-V Pharmaceutical Company (``Company'') has filed an application
with the Securities and Exchange Commission (``Commission''), pursuant
to Section 12(d) of the Securities Exchange Act of 1934 (``Act'') and
Rule 12d2-2(d) promulgated thereunder, to withdraw the securities
specified above (``Securities'') from listing and registration on the
American Stock Exchange LLC (``Amex'' or ``Exchange'').
The Securities have been listed for trading on the Amex and,
pursuant to a Registration Statement on Form 8-A which became effective
on March 25, 1999, on the New York Stock Exchange, Inc. (``NYSE'').
Trading in the Securities on the NYSE commenced at the opening of
business on March 25, 1999.
The Company has complied with the rules of the Amex by filing with
the Exchange a certified copy of the resolutions adopted by the
Company's Board of Directors authorizing the withdrawal of its
Securities from listing on the Exchange and by setting forth in detail
to the Exchange the reasons for such proposed withdrawal, and the facts
in support thereof. The Amex has in turn informed the Company that it
has no objection to the withdrawal of the Company's Securities from
listing on the Exchange.
In making the decision to withdraw its Securities from listing on
the Amex, the Company determined the following: (a) that listing on the
NYSE would enhance the overall value of the Company's Securities and
provide enhanced trading and other services to the Company's
stockholders; and (b) that withdrawal of such Securities from listing
on the Amex would avoid both the direct and indirect costs arising from
maintaining dual listings, as well as the resultant division of the
market for such Securities.
The Company's application relates solely to the withdrawal of the
Securities from listing on the Amex and shall have no effect upon the
continued listing of the Securities on the NYSE. By reason of Section
12(b) of the Act and the rules and regulations of the Commission
thereunder, the Company shall continue to be obligated to file reports
under Section 13 of the Act with the Commission and with the NYSE.
Any interested person may, on or before May 5, 1999, submit by
letter to the Secretary of the Securities and Exchange Commission, 450
Fifth Street, NW., Washington, DC 20549-0609, facts bearing upon
whether the application has been made in accordance with the rules of
the Exchange and what terms, if any, should be imposed by the
Commission for the protection of investors. The Commission, based on
the information submitted to it, will issue an order granting the
application after the date mentioned above, unless the Commission
determines to order a hearing on the matter.
For the Commission, by the Division of Market Regulation,
pursuant to delegated authority.
Jonathan G. Katz,
Secretary.
[FR Doc. 99-9907 Filed 4-20-99; 8:45 am]
BILLING CODE 8010-01-M
